NORCROSS -- Galectin Therapeutics, a leader in fibrotic disease and cancer research has announced plans to relocate its corporate headquarters from Boston to Norcross.
The business, which uses Galectin science and drug development to treat diseases, reportedly chose Gwinnett County because of its proximity to the University of Georgia's Complex Carbohydrate Research Center, one of the world's premier centers for carbohydrate research.
The Norcross facility will house Galectin Therapeutics' executive, strategic and development functions, while its Boston location will continue selected lab-based product development.
"This reorganization is an important move for the company that will strengthen our ability deliver on the promise of our carbohydrate-based therapeutic agents and afford us greater opportunities to attract highly-skilled talent in the field of carbohydrates to our company," said Peter G. Traber, president, chief executive officer and chief medical officer of Galectin Therapeutics.
Georgia Department of Economic Development Commissioner Chris Cummiskey said the company's relocation is a win-win.
"We welcome Galectin Therapeutics to Georgia's thriving bioscience community, where it will find numerous opportunities to collaborate with our outstanding research institutions," Cummiskey said. "The state has worked hard to cultivate an environment that will help bioscience companies grow, and Galectin Therapeutics' decision to locate here is a significant testimonial to the strength of our assets."
Local leaders too, said it was a plus for the area.
"We are fortunate that Galectin Therapeutics has chosen to relocate its business to Gwinnett and look forward to seeing them enhance our bioscience community," said Gwinnett County Commission Chairman Charlotte Nash.
For more information about the company, visit www.galectintherapeutics.com.